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A feasibility study evaluating an in situ formed synthetic
biodegradable membrane for guided bone regeneration in dogs
Abstract
PURPOSE: The aim was (1) to evaluate the soft-tissue reaction of a synthetic polyethylene glycol
(PEG) hydrogel used as a barrier membrane for guided bone regeneration (GBR) compared with a
collagen membrane and (2) to test whether or not the application of this in situ formed membrane will
result in a similar amount of bone regeneration as the use of a collagen membrane. MATERIAL AND
METHODS: Tooth extraction and preparation of osseous defects were performed in the mandibles of 11
beagle dogs. After 3 months, 44 cylindrical implants were placed within healed dehiscence-type bone
defects resulting in approximately 6 mm exposed implant surface. The following four treatment
modalities were randomly allocated: PEG+autogenous bone chips, PEG+hydroxyapatite
(HA)/tricalcium phosphate (TCP) granules, bioresorbable collagen membrane+autogenous bone chips
and autogenous bone chips without a membrane. After 2 and 6 months, six and five dogs were
sacrificed, respectively. A semi-quantitative evaluation of the local tolerance and a histomorphometric
analysis were performed. For statistical analysis, repeated measures analysis of variance (ANOVA) and
subsequent pairwise Student's t-test were applied (P<0.05). RESULTS: No local adverse effects in
association with the PEG compared with the collagen membrane was observed clinically and
histologically at any time-point. Healing was uneventful and all implants were histologically integrated.
Four out of 22 PEG membrane sites revealed a soft-tissue dehiscence after 1-2 weeks that subsequently
healed uneventful. Histomorphometric measurement of the vertical bone gain showed after 2 months
values between 31% and 45% and after 6 months between 31% and 38%. Bone-to-implant contact
(BIC) within the former defect area was similarly high in all groups ranging from 71% to 82% after 2
months and 49% to 91% after 6 months. However, with regard to all evaluated parameters, the PEG and
the collagen membranes did not show any statistically significant difference compared with sites treated
with autogenous bone without a membrane. CONCLUSION: The in situ forming synthetic membrane
made of PEG was safely used in the present study, revealing no biologically significant abnormal
soft-tissue reaction and demonstrated similar amounts of newly formed bone for defects treated with the
PEG membrane compared with defects treated with a standard collagen membrane.
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Abstract 
 
Purpose: The aim was 1) to evaluate the soft tissue reaction of a synthetic polyethylene-glycol (PEG) 
hydrogel used as a barrier membrane for GBR compared to a collagen membrane and 2) to test whether 
or not the application of this in situ formed membrane will result in a similar amount of bone 
regeneration as the use of a collagen membrane. Materials and Methods: Tooth extraction and 
preparation of osseous defects were performed in the mandibles of 11 beagle dogs. After 3 months, 44 
cylindrical implants were placed within healed dehiscence type bone defects resulting in approximately 
6mm exposed implant surface. The following 4 treatment modalities were randomly allocated: PEG + 
autogenous bone chips, PEG + hydroxyapatite(HA)/tricalciumphosphate(TCP) granules, bioresorbable 
collagen membrane + autogenous bone chips and autogenous bone chips without a membrane. After 2 
and 6 months 6 and 5 dogs were sacrificed, respectively. A semi-quantitative evaluation of the local 
tolerance and a histomorphometric analysis were performed. For statistical analysis repeated measures 
ANOVA and subsequent pairwise Student's t-test were applied (p<0.05). Results: No local adverse 
effects in association with the PEG compared with the collagen membrane was observed clinically and 
histologically at any time-point. Healing was uneventful and all implants were histologically integrated. 
Four out of 22 PEG membrane sites revealed a soft tissue dehiscence after 1-2 weeks that subsequently 
healed uneventful. Histomorphometric measurement of the vertical bone gain showed after 2 months 
values between 31 and 45% and after 6 months between 31-38%. BIC within the former defect area was 
similarly high in all groups ranging from 71-82% after 2 months and 49-91% after 6 months. However, 
with regard to all evaluated parameters the PEG and the collagen membranes did not show any 
statistically significant difference compared to sites treated with autogeneous bone without a membrane. 
Conclusion: The in situ forming synthetic membrane made of polyethylene-glycol was safely used in 
the present study revealing no biologically significant abnormal soft tissue reaction and demonstrated 
similar amounts of newly formed bone for defects treated with the PEG membrane compared to defects 
treated with a standard collagen membrane.  
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Introduction 
Guided bone regeneration (GBR) is the most commonly used technique to treat jaw bone areas with 
insufficient bone volume (for review see Hämmerle & Jung 2003). It is based on the concept of using a 
barrier membrane to create a space into which the bone can grow without interference of the soft tissues 
(Dahlin et al. 1989). The initial and successful use of expanded polytetrafluoroethylene membranes  
(ePTFE) as barriers has made this material the standard for guided bone regeneration (Dahlin et al. 
1991; Buser et al.1993). An obvious disadvantage of ePTFE materials is the fact that they are non-
resorbable and therefore have to be removed during a second surgical procedure. With regard to patient 
morbidity, risk for tissue damage, and cost versus benefits, the replacement of non-resorbable by 
resorbable membranes is highly desirable (Hämmerle & Karring 1998). Hence, research activities were 
directed towards the evaluation of resorbable membranes. The most commonly used resorbable 
membranes are made from collagen. In recent clinical studies, it has been demonstrated that the 
application of collagen membranes and bone substitutes in conjunction with the placement of dental 
implants lead to successful coverage of the previously exposed implant surfaces (Zitzmann et al. 1997; 
Hammerle et al. 1998; Jung et al. 2003; Moses et al. 2005). Since the risk of transmission of infecting 
agents can never be completely excluded for products originating from animals, synthetic barrier 
membranes made of polylactic or polyglycolide acid have been developed. Different polymer 
combinations have been developed to meet the criteria for the use as barrier membranes in GBR 
procedures and have been tested in animal models (Kohal et al. 1999; Stavropoulos et al. 2004).  
However, some studies have shown therapeutic problems using these traditional polymers because they 
acidify and can form proinflammatory fragments upon degradation (Schliephake et al. 1997; Meikle et 
al. 1994). 
Different experimental studies have introduced a newly developed synthetic hydrogel made of 
polyethylene glycol (PEG) for the use in bone regeneration therapy (Lutolf et al. 2003, Jung et al. 
2006). Polyethylene glycol has been shown to be highly biocompatible (Working et al. 1997; Pang et al. 
1993). It is presently approved for several pharmaceutical applications (Zalipsky & Harris 1997) and as 
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medical devices, e.g. a sprayable adhesion barrier (Mettler et al. 2003). In a recent animal study this 
PEG material was used for the first time as an in situ forming biodegradable membrane for GBR (Jung 
et al. 2006). It was demonstrated that the PEG membrane can successfully be used as biodegradable 
barrier membrane in the treatment of non-critical size defects in the rabbit skull and leads to similar 
amounts of bone regeneration as an ePTFE membrane. These results have driven further research to test 
the feasibility of this synthetic PEG material in a more clinically relevant model in dogs. 
The aim of the present study was twofold: 
1. to evaluate the soft tissue reaction of the synthetic PEG hydrogel when used as a barrier membrane 
for GBR compared to a standard resorbable collagen membrane 
2. to test whether or not the application of this in situ formed synthetic hydrogel will result in a similar 
amount of bone regeneration as a standard resorbable collagen membrane. 
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Materials and Methods 
Animals 
 
Eleven adult (14 months old) female beagle dogs (Harlan, France), weighing between 10 and 16 kg, 
were used in the present study. All animal experiments were performed at Biomatech NAMSA (Lyon, 
France). The animal facilities are accredited and registered at the French Department of Agriculture for 
animal housing, care and investigations. This study was conducted in accordance with the requirements 
of the FDA “Good Laboratory Practice” (GLP) Regulations (21 CFR 58 of April 1, 2002) and the 
“Bonnes Pratiques de Laboratoire (BPL), arrêté du 14 Mars 2000” described in the “Journal Officiel du 
Ministère Français de l’Emploi et de la Solidarité du 23 mars 2000”. The protocol was submitted and 
accepted by the internal Biomatech NAMSA ethical committee. 
 
Membranes and grafting materials 
 
The synthetic test membrane investigated in the present study was a polyethylene-glycol (PEG) based 
hydrogel.  Preparation of the PEG membranes was performed according to a previously published 
protocol (Jung et al. 2006). In brief, the membranes were made by mixing a multi-arm PEG with thiol 
endgroups and a multi-arm PEG with acrylate endgroups in an aqueous buffer system (triethanolamine 
/ HCl) at physiological pH (Institut Straumann AG, Basel, Switzerland). In this system, the PEG termini 
connect through a highly self-selective addition reaction, forming a network with hydrolizable ester 
linkages. The material was delivered in two syringes containing the PEGs dissolved  in buffer. 
Subsequently, the two syringes were attached to a static mixer and were ready to use.  
Collagen membranes (Bio-Gide®, Geistlich AG, Wolhusen, Switzerland) were used for positive 
controls. The collagen membranes were stabilized by using resorbable pins made of poly-lactic acid 
(Resor Pin®, Geistlich AG, Wolhusen, Switzerland).  
As grafting material either autogenous bone or synthetic hydroxyapatite (HA) / tricalciumphosphate 
(TCP) granules (Straumann Bone Ceramic®; Institut Straumann AG, Basel, Switzerland) were used. 
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The autogenous bone chips were harvested with a bone scraper (Safescraper® Micross, Meta company, 
Reggio Emilia, Italy) from the surrounding bone area. 
 
Preoperative treatment 
 
One week prior to each surgery an oral hygiene including dental calculus removal and desinfection was 
performed under drug sedation. Local disinfection with 0.2% chlorhexidine swabs was performed once 
a day for 3 days before surgery. Each animal was anesthetized according to a standard procedure: 
tranquillization by atropine (Atropine®, Aguettant, France), induction by tiletamine-zolazepam 
(Zoletil®100, Virbac, France) then thiopenthal sodique (NesdonalND, Merial, France) followed by 
inhalation of an O2 – N2O halothane (1-4 %) mixture (Halothane, Belamont, France).  
 
Surgery 1 (tooth extraction and defect preparation) 
 
Tooth extraction was performed after carefully elevating a full thickness flap and extracting bilaterally 
the lower premolars (P1, P2, P3, P4) and the first molar (M1). Subsequently, two bone defects were 
prepared on each side of the mandible, in such a way that the buccal bone plate was surgically removed. 
The dimension of each defect measured 12mm length, 8mm height and 6mm depth (Fig. 1 & 2). The 
lingual cortical bone wall was left intact. Wound closure was achieved using non-absorbable sutures.  
 
Surgery 2 (implantation and lateral ridge augmentation) 
 
Three months after surgery 1, implantation and regenerative surgery were performed.  Following a mid-
crestal incision as well as buccal vertical releasing incisions distal to the canine, a full thickness flap 
was carefully elevated. On each side of the mandible two sites with clinically healed bone surfaces 
exhibited bone volume deficiencies. In each of the 4 defects an experimental cylindrical implant with a 
large grit sandblasted and acid-etched (SLA) surface (Institut Straumann AG, Basel, Switzerland) was 
placed. The implants had a diameter of 3.3 mm and a length of 8 mm. The implants were placed in such 
a way that the shoulder was located at the level of the alveolar bone crest resulting in a buccal 
dehiscence defect of approximately 6 mm in vertical direction. Implant positioning according to this 
protocol allowed having standardized healed dehiscence type defects without the need for additional 
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defect adjustments (Fig. 3 & 4). At this time point, the vertical defect extensions were measured from 
the top of the implant shoulder to the first bone to implant contact at the mid buccal aspect. Following 
implant placement, perforations of the buccal bone plate were made to enhance bleeding using a round 
bur. The 4 implants inserted in each dog were randomly allocated to following 4 treatment modalities:  
− Group 1 : (Test 1) PEG biodegradable synthetic membrane + autogenous bone chips  
− Group 2 : (Test 2) PEG biodegradable synthetic membrane + HA/TCP granules  
− Group 3 : (Control 1) bioresorbable collagen membrane + autogenous bone chips 
− Group 4 : (Control 2) autogenous bone chips without a membrane 
 
At the test sites the PEG hydrogel was applied in a viscous liquid form over the bone graft material and 
the adjacent ridge in order to completely cover the defect and the implant and to extend 2 to 3 mm 
beyond the defect margins (Fig. 5 & 6). After approximately one minute, the PEG membrane had set to 
its gelated status. At the control sites the collagen membranes were trimmed and draped over the bone 
graft material and the adjacent ridge in order to overlap the defect margins 2 to 3 mm. Each membrane 
was secured at the buccal aspect with two resorbable pins and tucked underneath the lingual flap (Fig. 
7).  
To allow tension-free wound closure, the periosteum of the buccal flap was relieved along the entire 
base. Thereafter, primary wound closure was obtained with horizontal mattress and interrupted sutures. 
 
Clinical follow-up and observation 
 
Animals were observed daily and a detailed clinical follow-up was performed. The clinical aspect of 
soft tissue in the operated areas was recorded and photographs were taken once a week during the first 
month. 
 
Histological preparation 
 
One month prior to sacrifice, a single tetracycline labelling (Terramycine® 100, Pfizer, France) injection 
was administered in all dogs to allow an evaluation of the bone mineralization on histological sections. 
After 2 and 6 months following implantation and regenerative surgery, 6 and 5 dogs were sacrificed, 
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respectively. The animals were anesthetized by intramuscular injection in order to perform a fixation of 
the tissues by perfusion using approximately 500 mL of a 10% buffered formalin solution for each dog. 
The animals were then sacrificed by a lethal dose of pentobarbital. For histological evaluation, all sites 
were harvested with the intact surrounding soft tissues. The total of 44 sites were immersed in a 10% 
buffered formalin solution. Samples were dehydrated in alcohol solutions of increased concentrations 
and embedded in polymethylmethacrylate. From each specimen, two central orofacial sections through 
the implant were prepared for histological assessment. The final thickness (20-30 µm) of longitudinal 
sections through the defect was obtained by a microcutting and grinding technique (Donath & Breuner 
1982). Four of the sections from each dog were stained with modified Paragon for qualitative, semi-
quantitative and quantitative light microscopic analysis. The remaining four sections were kept 
unstained for UV light observation of the bone labelling.  
 
Semi-quantitative histological evaluation 
 
A semi-quantitative evaluation of the local soft tissue tolerance according to the ISO 10993-6 standards 
was performed for each site (evaluation of fibrin, necrosis, osteolysis, tissue degeneration, inflammatory 
reaction, neutrophils, eosinophilic, lymphocytes, plasma cells, macrophages, giant cells – fibrous 
encapsulation, cartilaginous tissue formation, neovascularization and any other relevant parameters). 
The grading scale used was:  0 = absent, 1 = slight, 2 = moderate, 3 = marked, 4 = severe.  
 
Quantitative histomorphometric analysis 
 
From each specimen the central orofacial section through the implant was selected for quantitative 
assessment by applying standard morphometrical techniques (Weibel 1980; Gundersen et al. 1988). 
Measurements were performed with a light microscope equipped with an analyzing system for color 
images (SAMBA®, SAMBA Technologies, France).  
The amount of newly formed bone was evaluated by the percentage of vertical bone gain at the buccal 
aspect of the implant. This was based on measuring the vertical distance (VD) between the original 
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buccal bone crest and the crest of the newly formed bone as well as the vertical defect measurements of 
the former dehiscence: 
Vertical distance of newly formed bone (VD) Vertical bone gain[%] = Vertical distance of the former defect × 100 
 
The degree of bone to implant contact was evaluated in the former defect area. The assessment was 
made from the most coronal level of bone to implant contact to the bottom of the former defect 
according to previously published protocols (Botticelli et al. 2003[a]; Jung et al. 2003).  
 
Statistical analysis 
Mean values and standard deviations were calculated for vertical bone gain, as well as for bone to 
implant contact. For statistical analysis repeated measures ANOVA and subsequent pairwise Student's t-
test with corrected p-values according to Bonferroni were used to detect the differences between the 4 
treatment modalities. The level of significance chosen in all statistical tests was set at p<0.05. 
 
 
 
 
 10 
Results 
2 months results 
Clinical observations 
 
During the experiment no reductions in body weights were noted, and no adverse effects were reported 
regarding all 6 animals. After 30 days all sites were healed normally except one site treated with the 
PEG membrane and autogenous bone revealing a very small opening (≤1mm) of the soft tissue. The 
observation at sacrifice revealed no macroscopic signs of local intolerance at any of the treated sites. 
 
Descriptive histology and semi-quantitative histological evaluation 
 
Due to angulations and malpositioning of 3 implants a histological analysis of the sections could not be 
performed because of missing tissue parts. These 3 implant sites, making up one site of group 1, 2  and 
4,  were therefore excluded from further analysis. The remaining 21 implants were well osseointegrated 
and showed in general a marked apposition of cortical bone or newly formed trabecular bone to the 
lingual implant surface with an endosteal bone ingrowth. The semi-quantitative histological observation 
revealed no biologically significant abnormal inflammatory response, infection or cellular change in the 
soft tissues in association with any of the treatment groups (Table 1). However, the inflammatory 
reaction observed around the PEG membrane was slightly greater to the one observed with the collagen 
membrane. 
Group 1 showed a few signs of autogenous bone chips that were embedded within the newly formed 
bone. Residual PEG hydrogel material was observed in 3 out of 5 samples. This group showed 
inconsistent results with slight to marked bone growth (Fig. 8).  
In group 2 HA/TCP granules were visible in varying amounts. They showed poorly osseointegrated and 
were encapsulated into a fibroconnective tissue. This treatment group showed slight to marked bone 
regeneration and was the most consistent compared to other groups. Two sites clearly showed presence 
of fragments of the PEG material. The number of inflammatory cells observed around the fragments 
was slightly greater than the one observed around the collagen membrane (Fig. 9).  
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In group 3 the autogenous bone chips were not evident. The collagen membrane was visible in all sites 
and was infiltrated by a limited number of macrophages. This treatment group showed inconsistent 
results with slight to marked bone regeneration (Fig. 10).  
Group 4 revealed no observable autogenous bone chips after 2 months of healing. This group 
demonstrated inconsistent bone growth with slight to marked bone regeneration (Fig. 11).  
 
Quantitative histomorphometric analysis 
 
Groups 2 and 3 showed the highest vertical bone gain (45 % and 44 % respectively), although no 
statistically significant difference was observed between the 4 treatment groups due to inconsistent 
results obtained in each group (Table 2).  
The bone-to-implant contact (BIC) within the former defect area was similarly high in groups 1, 2 and 4 
and ranged between 81 to 83%. Group 3 revealed a BIC of 71% with no statistically significant 
differences across the 4 treatment groups (Table 2).  
 
6 months results 
Clinical observations 
 
Three days after implantation and regenerative surgery signs of inflammation of the wound and 
desquamation of the surrounding epithelium were observed in almost all treated sites. The inflammation 
disappeared completely between 10 to maximum 20 days post-surgery. The inflammation was found to 
be attributable to the use of 2% chlorhexidine (CHX) instead of 0.2%. The daily application of the too 
highly concentrated CHX was stopped approximately 7 days after surgery.  After this event, 3 out of 10 
sites treated with the PEG membrane (1× group 1 and 2× group 2) showed an exposure of the 
membrane. These sites with membrane exposure healed uneventfully by secondary wound healing 
leaving part of the implant healing cap slightly visible at 30 days post-surgery. No other clinical 
abnormality was observed in the five animals in the course of the study following the initial 
inflammation. 
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Descriptive histology and semi-quantitative histological evaluation 
 
After 6 months all implants could be retrieved for histological analysis and revealed a good 
osseointegration. The semi-quantitative histological observation revealed no biologically significant 
abnormal reaction for any of the evaluated parameters within all treatment groups (Table 3). 
Group 1 did not reveal remaining autogenous bone chips. Two out of five sites showed residues of the 
PEG membrane. The suspected membrane remnants were infiltrated by a low number of macrophages. 
Results in this group varied to some degree and ranged from slight to marked bone growth (Fig.12). 
In group 2 the HA/TCP granules were visible in varying amounts within the treated sites. Two out of 
five sites did not reveal any HA/TCP particles anymore. In three sites remnants of the PEG hydrogel 
were detected which were infiltrated by macrophages. This treatment group showed moderate bone 
regeneration (Fig. 13). 
The autogenous bone chips were not observed any more in group 3. In four out of five sites the collagen 
membrane could be detected and was infiltrated by fibrocytes and by a limited number of macrophages. 
The results for this group varied, ranging between a slight to marked bone regeneration (Fig. 14). 
In group 4 no autogenous bone chips were observable in any of the treated sites. Results in this group 
varied, ranging from slight to marked bone regeneration (Fig. 15). 
 
Quantitative histomorphometric analysis 
 
Measurement of the vertical bone gain from the previous baseline showed no statistically significant 
differences across the 4 groups with a range between 31 and 38% bone gain (Table 4).  
The bone-to-implant contact (BIC) measured within the former defect showed the highest BIC values 
for groups 2 and 3 (90 ± 9% and 91 ± 11%, respectively) followed by group 1 (76 ± 21%) and group 4 
(49 ± 42%). No statistically significant differences were detected across the groups (Table 4). 
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Discussion 
With regard to the first aim of the present study, evaluating multiple parameters of the soft tissue 
reaction, no local adverse effects in association with the newly developed PEG membrane compared 
with a standard collagen membrane were observed after 2 and 6 months.  Concerning the second aim, 
the sites treated with the PEG membrane documented a similar amount of newly formed bone compared 
to defects regenerated with a collagen membrane. However, both membranes did not show a 
statistically significant difference compared to sites treated with autogeneous bone without a membrane.  
The PEG material has been successfully investigated in several preclinical studies for the use as a 
matrix system to release bioactive molecules (Lutolf et al. 2003; Jung et al. 2007 [a]; Jung et al. 2007 
[b]). The difference between the PEG material utilized as a matrix system and the presently used 
membrane lies in the chemical network structure. For membrane purposes the PEG hydrogel consists of 
multi-arm PEG molecules with more and shorter arms than those used for the matrix system. It was 
demonstrated that the PEG gels consisting of multi-arm PEG molecules are cell-occlusive, due to the 
fact that the distances between the cross-linking points are several orders of magnitude smaller than the 
dimensions of a cell (Wechsler et al. 2008). The barrier function was examined after subcutaneous 
placement of the PEG gels in rats. Histological analysis revealed prevention of cellular penetration in 
the membrane group up to 4 months (Wechsler et al. 2008). In a recent study the presently used PEG 
material has been successfully used to treat non-critical size bone defects in the rabbit skull (Jung et al. 
2006). After 4 weeks of healing, histomorphometrical analysis and micro-computed tomography 
demonstrated similar amounts of newly formed bone for defects treated with the PEG membranes 
compared to defects treated with a standard ePTFE membrane. The ePTFE and the PEG membranes 
revealed statistically significantly more bone formation compared to defects treated without a 
membrane.  
In addition to PEG as a matrix or a membrane for bone regeneration it is presently used in other medical 
disciplines. The safety and effectiveness of a sprayable PEG material used as a barrier system in 
laparoscopic surgery has been assessed in randomized, prospective, controlled, clinical trials (Mettler et 
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al. 2003). It was demonstrated that the PEG material was safe, well tolerated and there were no adverse 
effects attributed to the material and no patients in whom it could not be applied. These findings are in 
agreement with the present study evaluating multiple parameters of the soft tissue reaction to the PEG 
material. The clinical and semi-quantitative histological evaluation did not reveal any biologically 
significant abnormal reaction in association with the tested membrane materials. The presently used 
collagen membrane was chosen as control treatment because it is the standard of care in terms of 
resorbable membranes in GBR (for review see Hämmerle & Jung 2003) and it showed good soft tissue 
integration as well as cellular proliferation (Rothamel et al. 2004; Rothamel et al. 2005). In the present 
study, 6 months after regenerative surgery the collagen membranes were infiltrated with fibrocytes and 
macrophages whereas the PEG membrane revealed only macrophages. This points out that the PEG 
membrane is cell occlusive for a prolonged time also efficient during the course of degradation but it 
might also indicate a less favorable soft tissue integration.  
The clinical evaluation of the soft tissue coverage revealed a total of 9% dehiscences within all 44 sites 
after 28 days. However, all soft tissue dehiscences were found in the 22 sites treated with the PEG 
membrane revealing a membrane exposure rate of 18%. This rate lies within the range of similar dog 
studies showing an incidence of non-resorbable and resorbable membrane exposures from 20 to 60% 
(Buser et al. 1995; Von Arx et al. 2001; Oh et al. 2003). Two reasons may explain the findings in the 
present study. First,  3 out of 4 soft tissue dehiscences occurred in the group of animals treated with a 
too high concentration of CHX. After changing the CHX concentration to 0.2% the soft tissue recovered 
and only parts of the implant cover screw revealed visible. Hence, the sites with exposed PEG 
membranes healed subsequently without additional complications demonstrating that no membrane 
removal was necessary. Second, at both time-points (2 and 6 months), a slightly greater inflammatory 
reaction was observed for the PEG membrane compared to the collagen membrane. This delay in the 
soft tissue integration together with a high dosage of CHX might explain premature exposures of the 
synthetic PEG membrane. 
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The dog model is well established to evaluate the outcome of bone regeneration with and without 
implant placement (Buser et al. 1995; Von Arx et al. 2001; Kohal et al. 1999; Lima et al. 2003; Oh et al. 
2003). However, a large variety of defect shapes and sizes have been tested. The majority of these 
defects are acute defects prepared at the time of regeneration surgery. In contrast, the present study 
utilized defect situations mimicking healed dehiscence type osseous defects. Consequently, the inserted 
implants revealed their buccal surface exposed outside the bony envelope and no adjacent bone walls 
were present to support the membranes or protect the graft material. This defect can be considered to be 
challenging. 
The use of a PEG membrane or a collagen membrane in the present study revealed a vertical bone gain 
on the buccal side of the exposed implants of 32-45% after 2 and 6 months. These values are similar or 
smaller compared to dog studies using smaller and acute dehiscence type defects (Lima et al. 2003; Oh 
et al. 2003). One study using a nonresorbable ePTFE membrane revealed a vertical bone gain of 45-
86% after 4 and 6 months (Lima et al. 2003) and the other study showed a vertical bone gain of 57-67% 
for two resorbable collagen membranes after 4 months (Oh et al. 2003). In a further dog study using a 
similar acute dehiscence type defect a synthetic resorbable and a nonresorbable ePTFE membrane were 
investigated without the use of grafting materials (Kohal et al. 1999). After 6 months, a vertical bone 
gain of 51% could be observed in the nonresorbable membrane group whereas the resorbable membrane 
did no show any new bone formation. Bone regeneration was only detected at the base of the defect but 
minimal or no new bone formation was observed in the coronal, shallower defect part. These findings 
were attributed to a membrane collapse and the fact that the bony borders of the defects were too small 
to allow osteoprogenitor cells to repopulate the implant surface (Kohal et. al. 1999). In contrast, a recent 
dog study using saddle-type osseous defects demonstrated that a similar synthetic resorbable membrane 
was able to protect the defect and allowed a greater amount of bone regeneration compared to a 
standard collagen membrane (Stavropoulos et al. 2004). All these different and sometimes contradictory 
results within similar dog studies indicate that the outcome of bone regeneration using a variety of GBR 
materials depends very much on the size and shape of the bone defects. In the present study the 
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membrane groups were not able to show a statistically significant increase of the amount of vertical 
bone gain compared to autogenous bone without a membrane. Possible reasons are: a) the challenging 
defect design offering no adjacent bone walls to reduce the pressure of the alveolar mucosa on the 
augmentate, b) very little bone activity due the healed dehiscence type of bone defect, c) the tested 
resorbable membranes in combination with a grafting material showed insufficient mechanical 
properties to maintain the entire space for regeneration and d) due to gravity the graft material has been 
sagged apically. 
Although the vertical bone gain was moderate in the present study, the bone-to-implant contact (BIC) in 
the area of newly formed bone was very high in all treatment groups ranging from 49-91% after 2 and 6 
months (Fig. 16). Other dog studies reported BIC values of 11-45% (Oh et al. 2003), 29-47% (Kohal et 
al. 1999) and 68-77% (Botticelli et al. 2004). The BIC values of the present study indicate that a high-
quality bone and good implant integration was reached in the area of newly formed bone. This was true 
not only in the groups with autogenous bone but also in the group using a grafting material consisting of 
HA/TCP. However, the graft material was found to be mainly surrounded by fibroconnective tissue and 
showed a relatively low bone to substitute contact. This is in contrast to other clinical and animal 
studies reporting good osteoconductive properties of the same or similar graft material in different 
indications (Piattelli et al. 1996; Schwartz et al. 1999; Boix et al. 2004; Jung et al. 2007[b]). The reason 
for this observation is unclear. One possible explanation could be that some parts of the surface of this 
graft material undergo significant remodeling and hence mineralized bone is not directly deposited on 
the surface in those areas. This finding is supported by a recent clinical and histomorphometric study 
showing relatively high amount of newly formed bone with a low osteoconductivity when using 
HA/TCP (Cordaro et al. 2008). In addition, it is also known that the stability of the grafted area is a 
prerequisite for bone regeneration (Wikesjö & Nilveus 1990). Hence, it might be speculated that the 
insufficient mechanical protection of the graft material by the membranes and the gravity led to micro 
movements of the granules and, therefore, to a fibrous encapsulation.  
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One major advantage of the presently used PEG membrane is the clinical handling and the possibility to 
apply the membrane directly intra-operatively. Hence, no time is needed to cut and shape a standard 
preformed GBR membrane. In recent human and animal studies a membrane composed of polylactic 
acid dissolved in N-methyl-pyrrolidone has been investigated as a barrier in procedures aimed at 
regeneration of lost periodontal tissues (Garrett et al. 1997; Bogle et al. 1997). Although this material 
can be precipitated from solution in situ by adding water (Rosen & Reynolds 1999), in the majority of 
the studies a membrane made of the polymer was formed extraorally, before it was applied to cover the 
periodontal defect (Jepsen et al. 2000; Garrett et al. 1997). The favorable viscosity of the presently used 
PEG material makes this gel suitable for its clinical application without leakage of material into the 
adjacent areas. Hence, the PEG hydrogel used as a barrier membrane would represent an improvement 
for future GBR procedures.  
In conclusion, with regard to the first aim the in situ forming synthetic membrane made of polyethylene 
glycol was documented as safe in the present study revealing no biologically significant abnormal soft 
tissue reaction compared to a standard collagen membrane. Regarding the second aim, 
histomorphometrical analysis demonstrated similar amounts of newly formed bone for defects treated 
with the PEG membrane compared to defects treated with a standard collagen membrane. However, 
both membranes did not show a statistically significant difference compared to sites treated with 
autogeneous bone without a membrane. All inserted implants obtained after 2 and 6 months of healing a 
high percentage of bone to implant contact, irrespective of which of the 4 tested grafting techniques was 
used. 
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Fig 1: Defects created at the time of teeth extraction – buccal view 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2: occlusal view of the defects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3: Implants placed into the defects after three months of defect healing – buccal view 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: occlusal view of the implants after installation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5: Application of the PEG-Gel on autogenous bone chips 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6: Sites after augmentation procedures: autogenous bone chips alone (left) (group 4) and 
HA/TCP granules, covered with the PEG-Membrane (group 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7: Sites after augmentation procedure: autogenous bone chips, covered with bioresorbable 
collagen membrane, fixed with polylactide pins (left) (group 3) and PEG-membrane, applied 
onto autogenous bone chips (group 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8: Representative histological slide after 2 months of healing of group 1 treated with 
autogenous bone chips + PEG-membrane (arrow indicating the most coronal portion of newly 
formed bone) (Paragon stain, original magnification x 1)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9: Representative histological slide after 2 months of healing of group 2 treated with 
HA/TCP-granules + PEG-membrane (arrow indicating the most coronal portion of newly 
formed bone) (Paragon stain, original magnification x 1)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10: Representative histological slide after 2 months of healing of group 3 treated with 
autogenous bone + collagen membrane (arrow indicating the most coronal portion of newly 
formed bone) (Paragon stain, original magnification x 1)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 11: Representative histological slide after 2 months of healing of group 4 treated with 
autogenous bone chips alone (arrow indicating the most coronal portion of newly formed 
bone) (Paragon stain, original magnification x 1)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12: Representative histological slide after 6 months of healing of group 1 treated with 
autogenous bone chips + PEG-membrane (arrow indicating the most coronal portion of newly 
formed bone) (Paragon stain, original magnification x 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13: Representative histological slide after 6 months of healing of group 2 treated with 
HA/TCP-granules + PEG-membrane (arrow indicating the most coronal portion of newly 
formed bone) (Paragon stain, original magnification x 1)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14: Representative histological slide after 6 months of healing of group 3 treated with 
autogenous bone + collagen membrane (arrow indicating the most coronal portion of newly 
formed bone) (Paragon stain, original magnification x 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15: Representative histological slide after 6 months of healing of group 4 treated with 
autogenous bone chips alone (arrow indicating the most coronal portion of newly formed 
bone) (Paragon stain, original magnification x 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16: Representative histological slides after 2 months of healing of group 1 treated with 
autogenous bone chips + PEG-membrane (Fig. 16a) and of group 3 treated with autogenous 
bone + collagen membrane (Fig. 16b) revealing a high bone to implant contact in the area of 
the former bone defect (Paragon stain, original magnification x 8) 
 
Fig  16a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16b 
